TW200745034A - New compounds - Google Patents
New compoundsInfo
- Publication number
- TW200745034A TW200745034A TW095132103A TW95132103A TW200745034A TW 200745034 A TW200745034 A TW 200745034A TW 095132103 A TW095132103 A TW 095132103A TW 95132103 A TW95132103 A TW 95132103A TW 200745034 A TW200745034 A TW 200745034A
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrogen
- new compounds
- formula
- medicament
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 9
- 150000002431 hydrogen Chemical group 0.000 abstract 8
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- -1 pyridazinone derivative compound Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71282505P | 2005-09-01 | 2005-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200745034A true TW200745034A (en) | 2007-12-16 |
Family
ID=37607561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095132103A TW200745034A (en) | 2005-09-01 | 2006-08-31 | New compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090042856A1 (https=) |
| EP (1) | EP1919919A1 (https=) |
| JP (1) | JP5066516B2 (https=) |
| KR (1) | KR20080049758A (https=) |
| CN (1) | CN101268079B (https=) |
| AU (1) | AU2006285599A1 (https=) |
| BR (1) | BRPI0617100A2 (https=) |
| CA (1) | CA2620740A1 (https=) |
| IL (1) | IL189697A0 (https=) |
| NO (1) | NO20081572L (https=) |
| RU (1) | RU2008112290A (https=) |
| TW (1) | TW200745034A (https=) |
| WO (1) | WO2007026950A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200904421A (en) | 2007-05-03 | 2009-02-01 | Astellas Pharma Inc | New compounds |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| CN102099036B (zh) | 2008-06-03 | 2015-05-27 | 英特芒尼公司 | 用于治疗炎性疾患和纤维化疾患的化合物和方法 |
| KR101851518B1 (ko) * | 2010-09-08 | 2018-04-23 | 스미또모 가가꾸 가부시끼가이샤 | 피리다지논 화합물 및 그 중간체의 제조 방법 |
| MX355016B (es) | 2011-10-06 | 2018-04-02 | Bayer Ip Gmbh | Heterociclilpiri(mi)dinilpirazoles como fungicidas. |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN106604742B (zh) | 2014-07-03 | 2019-01-11 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| CN111153859B (zh) * | 2015-04-15 | 2021-09-03 | 江苏恩华药业股份有限公司 | 哒嗪酮类衍生物及其应用 |
| US10864203B2 (en) | 2016-07-05 | 2020-12-15 | Beigene, Ltd. | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018033135A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| JP6832430B2 (ja) | 2016-08-31 | 2021-02-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞代謝過程の阻害剤 |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11555038B2 (en) | 2017-01-25 | 2023-01-17 | Beigene, Ltd. | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| WO2018195155A1 (en) | 2017-04-18 | 2018-10-25 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| EP3645569A4 (en) | 2017-06-26 | 2021-03-24 | BeiGene, Ltd. | IMMUNOTHERAPY FOR LIVER CELL CARCINOMA |
| US11377449B2 (en) | 2017-08-12 | 2022-07-05 | Beigene, Ltd. | BTK inhibitors with improved dual selectivity |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US20220249491A1 (en) | 2019-06-10 | 2022-08-11 | Beigene Switzerland Gmbh | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356897A (en) * | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| AU4431000A (en) * | 1999-05-12 | 2000-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Novel use |
| US20040152659A1 (en) * | 1999-05-12 | 2004-08-05 | Fujisawa Pharmaceutical Co. Ltd. | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist |
| AUPQ441499A0 (en) * | 1999-12-02 | 2000-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel compound |
| WO2006038734A1 (en) * | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
-
2006
- 2006-08-31 WO PCT/JP2006/317691 patent/WO2007026950A1/en not_active Ceased
- 2006-08-31 CA CA002620740A patent/CA2620740A1/en not_active Abandoned
- 2006-08-31 CN CN2006800322174A patent/CN101268079B/zh not_active Expired - Fee Related
- 2006-08-31 BR BRPI0617100-1A patent/BRPI0617100A2/pt not_active IP Right Cessation
- 2006-08-31 TW TW095132103A patent/TW200745034A/zh unknown
- 2006-08-31 KR KR1020087007056A patent/KR20080049758A/ko not_active Ceased
- 2006-08-31 AU AU2006285599A patent/AU2006285599A1/en not_active Abandoned
- 2006-08-31 RU RU2008112290/04A patent/RU2008112290A/ru not_active Application Discontinuation
- 2006-08-31 EP EP06797567A patent/EP1919919A1/en not_active Withdrawn
- 2006-08-31 US US12/063,766 patent/US20090042856A1/en not_active Abandoned
- 2006-08-31 JP JP2008511498A patent/JP5066516B2/ja not_active Expired - Fee Related
-
2008
- 2008-02-24 IL IL189697A patent/IL189697A0/en unknown
- 2008-03-31 NO NO20081572A patent/NO20081572L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090042856A1 (en) | 2009-02-12 |
| EP1919919A1 (en) | 2008-05-14 |
| IL189697A0 (en) | 2008-06-05 |
| CN101268079A (zh) | 2008-09-17 |
| JP2009507758A (ja) | 2009-02-26 |
| CN101268079B (zh) | 2011-09-14 |
| NO20081572L (no) | 2008-03-31 |
| BRPI0617100A2 (pt) | 2011-07-12 |
| JP5066516B2 (ja) | 2012-11-07 |
| KR20080049758A (ko) | 2008-06-04 |
| CA2620740A1 (en) | 2007-03-08 |
| AU2006285599A1 (en) | 2007-03-08 |
| WO2007026950A1 (en) | 2007-03-08 |
| RU2008112290A (ru) | 2009-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200745034A (en) | New compounds | |
| MX2009010024A (es) | Nuevo compuesto de adenina. | |
| TW200730514A (en) | Morpholine type cinnamide compound | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| TW200642683A (en) | Heterocyclic compound | |
| MY172034A (en) | Intermediate for producing bicyclic ?-amino acid derivative | |
| TW200626559A (en) | Anilino-pyrimidine analogs | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| NO20075312L (no) | N-(N-sulfonylaminometyl)cyklopropankarboksamidderivater nyttige ved smertebehandling | |
| TW200606137A (en) | Urea derivatives | |
| UA105185C2 (uk) | Піроли | |
| MX2009003927A (es) | Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes. | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| PH12012501711A1 (en) | [5,6] heterocyclic compound | |
| WO2008108380A3 (en) | Pyrrole compounds | |
| MXPA05008619A (es) | Derivados novedosos de 2-piridincarboxamida. | |
| DE60129210D1 (de) | Zyklische amid-derivate | |
| WO2009069736A1 (ja) | 含窒素化合物 | |
| MX2009007482A (es) | Agentes antiparasitarios. | |
| UA95972C2 (ru) | Аминопиридиновые производные с селективной ингибирующей активностью в отношении авроры а | |
| GB0413087D0 (en) | Therapeutic compounds | |
| MY169179A (en) | Novel piperidine compound or salt thereof | |
| TW200744659A (en) | Preparation for preventing and ameliorating wrinkle | |
| MX2009008756A (es) | Compuesto macrociclico. | |
| MY139612A (en) | Benzoxazine derivatives as 5-th6 modulators and uses thereof |